Aethlon Medical, Inc

Aethlon Medical is headquartered in San Diego, California and is incorporated in Nevada, with U.S. operations driving corporate management and R&D oversight. The company’s commercialization plans contemplate both U.S. and international markets, but foreign market entry would require successful human trials and approvals by non-U.S. regulatory agencies. The firm has demonstrated at least limited international clinical use under emergency conditions (e.g., a single-patient Ebola emergency use at Frankfurt University Hospital in Germany), indicating potential global clinical interest but not established commercial presence. Geopolitical and macro conditions (inflation, bank failures, and conflicts including Russia–Ukraine and Israel and surrounding areas) are monitored primarily for their impact on capital markets, timelines, and access to financing rather than for current revenue exposure.

Aethlon faces development-stage risk: the Hemopurifier is not yet commercialized and its prospects depend on successful clinical trials and regulatory clearance in the U.S. and abroad. The company discloses substantial financing risk, including ongoing losses and the need for additional capital that could dilute existing shareholders, with macro shocks (inflation, bank failures, geopolitical conflicts) potentially tightening capital availability and extending timelines. Operationally, the device relies on third-party suppliers and manufacturing partners; delays, interruptions, or failure to meet GMP requirements can prevent or delay production and trials. Even with clearance, reimbursement risk is significant because hospital purchasing is closely tied to CMS/private payor coverage decisions and health technology assessments, and the technology could be displaced by more effective or economical competing modalities (including competing blood filters).